IGC Pharma, Inc. (IGC)
(Delayed Data from AMEX)
$0.34 USD
0.00 (-1.01%)
Updated Aug 6, 2025 03:54 PM ET
After-Market: $0.34 0.00 (-1.36%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IGC 0.34 0.00(-1.01%)
Will IGC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IGC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IGC
IGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue Estimates
Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates
IGC: What are Zacks experts saying now?
Zacks Private Portfolio Services
IGC Pharma, Inc. (IGC) Reports Q3 Loss, Tops Revenue Estimates
IGC Pharma, Inc. (IGC) Upgraded to Strong Buy: What Does It Mean for the Stock?
What Makes IGC Pharma, Inc. (IGC) a New Buy Stock
Other News for IGC
IGC Unveils Promising Preclinical Data for Alzheimer's Molecule IGC-M3
IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of ...
IGC Pharma announces preclinical data on IGC-M3
IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression
IGC Showcases AI Innovations at 2025 Alzheimer's Conference | IGC Stock News